AROICON 2024
Our Three Pillars
At Accuray we stand on three pillars: Quality of Care, Efficiency in Care and Confidence in Care. These pillars underpin our resolute commitment to enhancing the landscape of radiation therapy in innovating care.
Quality of Care
Efficiency of Care
Confidence in Care
Expand Access to Radiation Therapy Treatments to More Patients
Exclusive Preview: Accuray Helix Launched at ICC2024, with More Updates Coming at AROICON
Educational Demonstrations at AROICON 2024
BOOST PLANNING EFFICIENCY
Create and adapt precise, customized treatment plans in less time
ENHANCE USER EXPERIENCE
Automate workflows and provide state-of-the-art treatment planning tools.
IMPROVE PATIENT OUTCOMES
Deliver more personalized and more precise treatment plans for more patients.

Join AEx for Exciting Webinars from your Peers!
Community Engagement: Connect. Exchange. Learn.
Meet the Accuray Team
Interact with Accuray experts and gain insights into our cutting-edge solutions.
Talk to an Expert
Accuray Symposium
Expert Encounters: A Live Debate on the Merits and Controversies of SBRT and ADT in the Management of Prostate Cancer
Join us at our symposium hosted at ASTRO for two invigorating debates that delve into the forefront of prostate cancer therapies. Prepare to engage as we navigate through contrasting perspectives on topics that are reshaping the trajectory of modern prostate cancer treatment with SBRT and ADT. This event promises to be a platform for lively exchange, allowing radiation oncologists, physicists, radiation therapists, and nurses to broaden their perspectives. Share in compelling discussions as Radiation Oncologist thought leaders debate differing viewpoints on contemporary topics that highly impact prostate cancer care.
Introduction & Conclusion
Dr. Seth Blacksburg, SVP, Chief Medical Officer, Accuray
Debate #1 Moderated by Dr. Jon Haas
ADT is a Critical Component in the Management of UPCa in the Modern Era.
Dr. Amar Kishan vs Dr. Mack Roach
Debate #2 Moderated by Seth Blacksburg
Prostate SBRT has emerged as the ablative therapy of choice for the majority of prostate cancer.
Dr. Richard Stock vs Dr. Robert Timmerman